市場調查報告書
商品編碼
1410884
萊姆病檢測市場:市場規模(按細分市場)、份額、監管、報銷、預測(~2033)Lyme Disease Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
萊姆病是一種由伯氏疏螺旋體細菌引起的發炎性疾病,透過受感染的硬蜱叮咬傳播。
萊姆病檢測包括萊姆病酵素免疫分析(EIA)檢測、萊姆病蛋白質印跡檢測及萊姆病NAAT(核酸擴增檢測)等檢測。
本報告深入探討了全球萊姆病檢測市場,包括競爭格局、SWOT 分析、到 2033 年的市場預測、COVID-19 的影響以及區域和國家趨勢。
Lyme Disease Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on Lyme Disease tests market for the year 2020 and beyond.
Lyme Disease is an inflammatory disease caused by the bacterium Borrelia burgdorferi and is transmitted through the bite of infected ticks of the genus Ixodes.
Lyme Disease tests are performed to evaluate the disease which can occur in three stages:
The Lyme Disease tests include Lyme Disease Enzyme Immuno Assay (EIA) Tests, Lyme Disease Western Blot Tests, and Other Tests which include Lyme Disease NAATs (Nucleic Acid Amplification Tests).
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed Lyme Disease Test and evolving competitive landscape:
Global, Regional and Country level market specific insights:
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Thermo Fisher Scientific Inc, Revvity Inc, bioMerieux SA, Bio-Rad Laboratories Inc, Qiagen NV, Meridian Bioscience Inc, Trinity Biotech Plc, DiaSorin SpA, Quidelortho Corp, ERBA Diagnostics Inc, ZEUS Scientific Inc, Viramed Biotech AG, and Others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -
Not Applicable
Not Applicable
Not Applicable